Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.

@article{Czuczman2016PevonedistatAN,
  title={Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.},
  author={Natalie M Czuczman and Matthew J. Barth and Juan J Gu and Vishala T Neppalli and Cory Mavis and Sarah E Frys and Qiang Hu and Song Liu and Pavel Klener and Petra Vo{\vc}kov{\'a} and Myron S. Czuczman and Francisco J Hernandez-Ilizaliturri},
  journal={Blood},
  year={2016},
  volume={127 9},
  pages={1128-37}
}
Mantle cell lymphoma (MCL) is characterized by an aggressive clinical course and inevitable development of refractory disease, stressing the need to develop alternative therapeutic strategies. To this end, we evaluated pevonedistat (MLN4924), a novel potent and selective NEDD8-activating enzyme inhibitor in a panel of MCL cell lines, primary MCL tumor cells, and 2 distinct murine models of human MCL. Pevonedistat exposure resulted in a dose-, time-, and caspase-dependent cell death in the… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 36 references

The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2015
View 2 Excerpts

Similar Papers

Loading similar papers…